NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1109 coverAutoimmunity, Part A Basic Principles and New Diagnostic Tools Volume 1109 published September 2007
Ann. N.Y. Acad. Sci. 1109: 117–128 (2007). doi: 10.1196/annals.1398.014
Copyright © 2007 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via Google Scholar
Google Scholar
Articles by ROSE, N. R.
Search for Related Content
PubMed
PubMed Citation
Articles by ROSE, N. R.

Part I. New Principles of Autoimmunity

Prediction and Prevention of Autoimmune Disease

A Personal Perspective

NOEL R. ROSEa

a Departments of Pathology and of Microbiology and Immunology and the Johns Hopkins Center for Autoimmune Disease Research, Johns Hopkins University, Baltimore, Maryland, USA

Key Words: autoimmunity • thyroid • thyroiditis • Hashimoto's disease • hypothyroidism • Graves' disease • hyperthyroidism • thyroglobulin • thyroperoxidase

Portions of this article were published in a special supplement to the May 2007 issue of The Scientist. Address for correspondence: Noel R. Rose, M.D., Ph.D., Johns Hopkins Center for Autoimmune Disease Research, Johns Hopkins University, 615 N. Wolfe St., MMI E5009, Baltimore, MD 21205. Voice: 410-955-0330; fax: 410-955-0105.  nrrose{at}jhsph.edu

Biomarkers, represented by genetically determined traits or biologic changes predictive of disease onset or outcome, are increasingly employed by academic and industrial investigators. They can identify unusually susceptible populations or individuals, facilitate prognosis, forecast the outcome of therapy in clinical trials, or aid in developing improved treatments or preventative measures. All of these applications have been applied to the autoimmune diseases. As a case in point, we have through the years used biomarkers to predict susceptibility and the longer-range outcome of thyroid autoimmunity employing, a number of different approaches. They have taught us valuable lessons for future broader applications of biomarkers. The clues for susceptibility include major histocompatibility complex (MHC) and non-MHC genes combined with the fine specificity of thyroid autoantibodies in siblings of patients with juvenile thyroid disease. Together these biomarkers are highly predictive of later thyroid autoimmunity and subclinical thyroid dysfunction. For example, the progression from benign autoimmunity to clinical thyroid disease is marked by the appearance of autoantibodies to species-restricted epitopes on thyroglobulin. Thus, predictive biomarkers aid in identifying individuals with inordinate risk of disease and provide opportunities for earlier interventions to arrest the disease process.






footerLeft footerRight